CATHERINE LE: Open Payments
NPI 1932144656 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,458 in 35 payments from 14 companies in 2025. Trend: 2023 $620 · 2024 $659 · 2025 $1,458
Food & beverage: $1,458
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $327 |
| Janssen Biotech, Inc. | 5 | $318 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $223 |
| Regeneron Pharmaceuticals, Inc. | 1 | $124 |
| Madrigal Pharmaceuticals | 1 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $78 |
| Ardelyx, Inc. | 3 | $75 |
| Aimmune Therapeutics, Inc. | 2 | $54 |
| Novo Nordisk Inc | 1 | $42 |
| Ferring Pharmaceuticals Inc. | 2 | $35 |
Products named: TREMFYA, XIFAXAN, DUPIXENT, RINVOQ, REZDIFFRA, IBSRELA, CREON, ENTYVIO.
Industry payments across IN — which companies pay providers there.
